Sentences with phrase «companies over price»

Off - topic but relevant... «Trougher» Yeo was on telly yesterday - interviewed on the usual subject of the government bashing the energy companies over the price of their tariffs (not ONE mention of the in - built cost of the subsidies / feed - in tariffs to «renewables» - quel surpris)..

Ricks also addressed President Donald Trump's decision to lambast pharmaceutical companies over the price of prescription drugs, in his State of the Union address Tuesday evening.

Not exact matches

Pricing power — meaning how consumer demand would be affected if your company shifted its prices — is one detail that often gets excluded from business plans, but which can help put you over the edge.

Oil prices rose on Tuesday as companies prepared to suspend production in the U.S. Gulf over a looming tropical storm.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Larry Puglia, whose T. Rowe Price Blue Chip Growth Fund has trounced the S&P 500 with annualized returns of 18.5 % over the past five years (and 37 % in 2017 alone), says that some of the same companies he avoided around the turn of the millennium are now among the biggest holdings in his portfolio, including Amazon (amzn), Alphabet (googl), and Microsoft (msft).

The two companies have been at odds over pricing and promotion on the Amazon website.

The more investors there are vying for a product, the greater control a company has over setting the price.

This Toronto - based property and casualty insurance company has increased its dividend by more than 50 % over the past three years while its stock price has climbed from $ 35 to $ 62.

firm to Enron and cutting the stock price in half over the following few days (the report, though hyperbolic, helped trigger greater scrutiny of the company.)

The minor disappointment translated into a huge decline in the company's stock price, erasing over $ 10 billion in market value over the past day - and - a-half.

The co-founders wanted $ 200,000 for 12.5 percent, but after the other sharks backed out over concerns about the company's product and high price, they were left with just O'Leary's offer.

The share prices of big entertainment companies have been extremely volatile over the past year as investors try to assess the winners and losers in the changing video ecosystem.

Miller, chief investment officer at LMM, said he thinks the embattled drugmaker is «a completely different company» than the one that was under severe fire for jacking up drug prices, and could see returns of 25 percent to 30 percent per year over the next five years.

Specifically, Defendants made false and / or misleading statements and / or failed to disclose that: (i) Akorn's failure to comply with FDA data integrity requirements would jeopardize Fresenius» acquisition of Akorn; (ii) the Company lacked effective internal controls over financial reporting; and (iii) as a result of the foregoing, Akorn shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.

• Social Finance Inc, a San Francisco - based student loan refinancing services company, discussed a potential sale earlier this year with Charles Schwab Corp, but the talks fell apart over the $ 8 billion price the online lender sought, according to Reuters.

In 2013, for example, Magnetar and several other hedge funds sued over the acquisition by 3M (mmm) of biometrics company Cogent, seeking about 55 % more money for their shares in the target, which they claimed were priced too low.

«Volumes are forecast to fall by 0.1 percent as price rises, which came into play as a result of the weakened pound, will discourage cash strapped consumers from shopping over the seasonal period,» the research company said.

Valeant has been at the center of a political firestorm over prescription medication costs and pharmaceutical companies, which depend more on acquiring or licensing existing therapies (and then raising their prices) rather than fueling R&D into new drugs.

The company said in February that it planned to buy back up to $ 5 billion of stock over 2018 - 2020 to share the benefits of higher oil prices with investors.

Apple's stock dipped at the start of 2016 due to concerns over a slowdown in iPhone sales, though share prices have since rebounded into positive territory for the year amid investor optimism for the company's new line of products.

On the surface, Papa seems to have gotten an extraordinarily generous deal to turn around the beleaguered drug company: Not only is his salary more than twice what it was when he was CEO of Perrigo (prgo), a company nearly three times as valuable as Valeant (vrx), it's also especially good considering Valeant's stock price has fallen nearly 67 % since he took over.

The company hands over, say, $ 100 million, in exchange for a percentage of what's produced at a set price.

At that price, he would collect $ 800 million, or $ 200 million a year over four years — making more than the CEOs of more than a dozen major pharma companies are likely to be paid, combined.

Over in the House of Representatives, Democrats have also been hot on the tail of pharmaceutical companies that have jacked up the prices of some of their drugs, though they've making less headway than their Senate bipartisan counterparts.

The company has avoided much of the issues that have derailed its peers, and while its stock price did take a hit over the summer after it cut its production guidance, it's still in good shape.

The result, Osterweis says, is that investors through index funds get trapped in a few companies, and it's the same companies everyone else is buying, so they tend to be over priced.

But inflation remains distant from the BOJ's 2 percent target as companies hold off on raising prices and wages, citing uncertainty over the economic outlook.

Biogen is among companies that have been singled out for criticism in recent months; the Wall Street Journal called out the company for hiking the price of MS drug Avonex — 21 times, and at an annual average rate of 16 % — over the past decade.

In periods of rising volatility, pharma companies are often especially vulnerable because of investors are paying big prices today for therapies expected to pay off over a long horizon.

The U.S. Department of Justice has sued to block the deal over concerns about the companies» pricing power in the media market.

* But there is also a valid policy argument that companies that own both cable channels and cable wires have excessive power over pricing, and that blocking such a merger is a good use of anti-trust power — even if it's an argument you'd usually hear from the left side of the aisle.

However new complaints flared up on the company's Facebook page in October over sheerness and pilling with its premium - priced pants.

Shan thinks it could hit $ 45 over the next 12 months, while Blondeau has a $ 42 price target on the company.

Bresch was forced to testify before Congress, and the company's stock price has plunged nearly 13 % over the past year.

«It turns out 4 to 5 percent is enough of a discount for shoppers,» CEO Marc Lore said, discussing the results of tests the company ran over the past few weeks by raising the prices of some products.

The unexpected boom in U.S. natural gas production over the last decade has pushed down power prices, making it harder for companies that operate plants to turn a profit.

The approach has worked wonders for Apple, giving that company full control over the quality and price of its products, and even Google looks to be leaning that way too with its Nexus phones and tablets, not to mention its Motorola subsidiary.

Companies that have aggressive accounting where management is pulling the wool over investors» eyes and artificially propping up their stock price can lead to solid returns, even in a bull market.

Levie said the company has a «pretty long - term perspective around the stock price,» and he's hopeful it will rise over time because Box is a «$ 340 million company going at a $ 40 billion market.»

And the tactic isn't all that surprising: big pharma's return on R&D investments has been plummeting over the last decade, and price increases are an easy way to bolster companies» bottom lines.

The exact share exchange ratio will be determined by looking at the volume - weighted average stock price of the companies over the last few months, one of the sources added.

A deal is by no means assured in light of the company's uncertain financial prospects and steep price tag — its market value is more than $ 16 billion after talk of a sale drove the stock up over the past few days.

According to Panera, the growth in the MyPanera program has allowed the company to significantly increase the efficiency of its marketing, and perhaps not coincidentally, over the past year, the company's stock price has increased almost 30 percent.

The combined price tag for Brami's list tops $ 300,000, a sizable chunk for a 25 - employee company, so he'll likely spread out the investments over the next year.

It's down about 14 % to $ 2.45 on Thursday at the time of publishing, a far cry from the company's stock price of over $ 14 per share in 2012.

While the bulk wine companies are focused on the lower end of the market and price that way, the premium producers go over the top on every element of the wine making process.

A majority of female business owners expect their companies to grow over the next two years, but most don't want to raise prices — and they'd like to avoid risk, says a new report.

«Samsung expects to see its sales of mobile devices increase with the rollout of flagship products and new models, but profitability may suffer due to a heated race over price and product specifications,» the company said in July.

The negotiation would always break down over price, so we hired an adviser who has her own company.